The rodent efficacy data presented here suggest that all 3 G-CSF/IgG-Fc fusion proteins would be effective in cancer patients using a once per chemotherapy cycle dosing regimen, similar to the dosing regimen used for PEG-G-CSF. This evidence concerns the gene CSF3 and cancer.